Top news of the week: 31.03.2020.
Bill & Melinda Gates Foundation, Antibody, Drugs, In vivo, Bristol-Myers Squibb, Smallpox
Startups
RT @HalloranConsult: Some interesting thoughts from @statnews on what it’s like to go into the lab at a #biopharma company during the #coronavirus pandemic, featuring our CEO, @LaurieAHalloran, and COO, @GDombal. Read more here: https://t.co/rVm1YoRXsO
OpenWhat it’s like to go into the lab at a biopharma company during the coronavirus pandemic
Biopharma companies are navigating once-unimaginable questions: Which research and manufacturing projects can wait? Which can’t?
RT @LifeSciVC: Strategic Planning In Biotech During A Pandemic Crisis.
This is the Goldilocks moment for many biotechs: not too hot and not too cold. Preserving near term optionality while planning for and adapting to the longer term scenarios.
https://t.co/2OpXgzujTc https://t.co/bigb1e9TV3
OpenStrategic Planning In Biotech During A Pandemic Crisis
In the throes of a full COVID-19 pandemic, most business leaders’ top priority is rightfully the health and safety of their employees, families, and communities. Even though business ...
Moderna has paused enrollment in some of their infectious and rare disease clinical trials in response to covid-19 pandemic disruptions. Story said Moderna's cancer trials still enrolling patients at this time & "evaluating the initiation of new sites." https://t.co/CnBswYYeG4
OpenCOVID-19 causes Moderna to pause a clutch of clinical trials
Moderna has become the latest company to hit pause on clinical trials in response to the COVID-19 pandemic. The biotech, which is leading efforts to develop a COVID-19 vaccine, is pausing ...
An entreaty on the importance of diagnostic tests going forward, from @MichaelPellini.
https://t.co/7xD66ejwMP
OpenKnowledge is Power: Don’t Give Up on Diagnostic Tests for COVID19
Let’s not mince words. We are in the midst of the worst health care emergency since the flu pandemic of 1918-19 that killed 650,000 Americans and 50 million people worldwide. And, we are ...
RT @adamfeuerstein: Biotech VC Bob Nelsen called it right on the #coronavirus. Now he has thoughts on therapeutics —and masks (We should all be wearing them, when available) https://t.co/RUnIMeKtxx I spoke to @rtnarch this weekend.
OpenBiotech VC Bob Nelsen called it right on the coronavirus. Now he has thoughts on therapeutics — and masks
An interview with the co-founder and managing partner of Arch Venture Partners on where he thinks the pandemic is going and how we get out of it.
These are the five key experimental drugs which await the FDA's approval in the second quarter:
https://t.co/BMJuXThV00
Open5 FDA approval decisions to watch in the 2nd quarter
The FDA's focus is squarely on responding to COVID-19, yet the agency continues to review new drugs for other diseases. Among them: Roche's SMA therapy risdiplam and Intercept's NASH drug.
Big Pharma companies join forces for fightback against COVID-19
A who’s who of leading biopharma companies have joined forces to strengthen the drug industry’s response against the COVID-19 pandemic. Companies including Novartis and Pfizer are ...
: With China returning to work, preclinical companies ramping back up, @adamfeuerstein writes. https://t.co/gESWlMuyjt via @statnews
OpenBiotech in the time of the coronavirus: With China returning to work, preclinical companies ramping back up
In this edition: Chinese labs returning to work; a look at prescription drug data; more corporate updates; and another super-cute dog pic.